ENBI — Entheon Biomedical Cashflow Statement
0.000.00%
Last trade - 00:00- CA$1.66m
- CA$1.14m
- 31
- 15
- 30
- 14
Annual cashflow statement for Entheon Biomedical, fiscal year end - November 30th, CAD millions except per share, conversion factor applied.
2020 March 31st | 2021 November 30th | 2022 November 30th | 2023 November 30th | 2024 November 30th | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -0.147 | -8.89 | -2.06 | -0.3 | -0.318 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.036 | 2.35 | 0.156 | -0.003 | 0 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.008 | 0.437 | 0.437 | -0.057 | -0.038 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -0.102 | -5.62 | -1.47 | -0.36 | -0.356 |
| Capital Expenditures | -0.085 | -0.098 | — | — | — |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | -0.001 | 0.609 | 0.024 | 0 |
| Sale of Business | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.085 | -0.099 | 0.609 | 0.024 | 0 |
| Financing Cash Flow Items | 0.095 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.095 | 4.98 | 0 | — | 0.147 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -0.092 | -0.738 | -0.857 | -0.336 | -0.208 |